IGF2BP1–THBS1 Axis Drives Macrophage Glycolysis in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive, often fatal disorder marked by excessive fibroblast proliferation and extracellular matrix deposition, leading to irreversible lung scarring. The pathogenesis of PF involves a dynamic interplay between immune cells, fibroblasts, and metabolic reprogramming. Macrophages, particularly those exhibiting an M2 phenotype, are recognized as major contributors to fibrosis, promoting tissue remodeling and the secretion of profibrotic cytokines. While the importance of metabolic shifts—such as enhanced glycolysis—in fibrotic progression is established, the upstream regulatory mechanisms remain incompletely defined. Notably, RNA modifications like N6-methyladenosine (m6A) have emerged as central modulators of mRNA stability and translation in disease contexts. The reference study sought to clarify how IGF2BP1, an m6A reader protein, influences macrophage function and fibrotic outcomes in PF.

Key Innovation from the Reference Study

The central innovation lies in delineating an IGF2BP1–THBS1–TLR4 axis that connects epitranscriptomic regulation with macrophage metabolic programming and polarization. The study demonstrates that IGF2BP1, upregulated in PF macrophages, binds to and stabilizes THBS1 mRNA in an m6A-dependent manner. Stabilized THBS1, in turn, interacts with toll-like receptor 4 (TLR4), promoting M2 macrophage polarization and a glycolytic metabolic state that supports fibrotic progression. This mechanistic link provides a direct molecular route from m6A-dependent posttranscriptional regulation to cell phenotype changes driving fibrosis, offering potential new targets for therapeutic intervention.

Methods and Experimental Design Insights

The authors employed a combination of in vivo and in vitro models to dissect the role of IGF2BP1 in pulmonary fibrosis. Key methodological highlights include:

• Animal Model: Bleomycin (BLM)-induced pulmonary fibrosis was established in mice, a widely accepted model for recapitulating key features of human PF.
• Gene Manipulation: IGF2BP1 knockdown was achieved in vivo via genetic approaches and in primary cells using siRNA, allowing assessment of its role in disease progression.
• Molecular Characterization: Quantitative PCR, Western blotting, and immunohistochemistry were used to profile expression levels of IGF2BP1, THBS1, and PF-associated markers (e.g., TGF-β1, α-SMA, Collagen-I/III).
• Metabolic Assessment: Glycolytic flux was evaluated by measuring key glycolytic enzyme expression (HK2, LDHA, PKM2), lactate production, glucose uptake, and ATP generation in macrophages.
• Rescue Experiments: Overexpression of THBS1 and TLR4 was performed to test causal links between these molecules and observed phenotypes in IGF2BP1-deficient settings.
• RNA–Protein Interaction: RNA immunoprecipitation and m6A site mapping confirmed direct binding of IGF2BP1 to m6A-modified THBS1 mRNA.

Core Findings and Why They Matter

The reference study reported several pivotal observations:

• IGF2BP1 Overexpression in PF Macrophages: Macrophages from fibrotic lungs exhibited markedly elevated IGF2BP1 levels.
• IGF2BP1 Knockdown Attenuates Fibrosis: Reducing IGF2BP1 expression led to decreased inflammatory infiltration, less fibroblast accumulation, and lower Ashcroft fibrosis scores, indicating amelioration of PF pathology.
• Suppression of PF-Associated Markers: IGF2BP1 knockdown downregulated key profibrotic and inflammatory markers, including TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, CD163, IL-6, IL-1β, and TIMP1.
• THBS1 as a Direct IGF2BP1 Target: Mechanistic studies confirmed that IGF2BP1 stabilizes THBS1 mRNA via m6A binding. Loss of IGF2BP1 decreased THBS1 levels, while THBS1 overexpression reversed the suppression of M2 polarization and glycolysis observed in IGF2BP1-deficient macrophages.
• Glycolytic Reprogramming: Restoration of THBS1 in IGF2BP1-depleted cells rescued glycolytic enzyme expression and metabolic activity, underpinning the connection between THBS1 and glycolysis.
• THBS1–TLR4 Interaction: THBS1 physically interacted with TLR4, and TLR4 overexpression compensated for THBS1 loss, reinstating M2 polarization and glycolytic metabolism.

These results establish a regulatory circuit wherein IGF2BP1-driven THBS1 stabilization enables TLR4-mediated metabolic and phenotypic changes in macrophages. The findings not only clarify how epitranscriptomic mechanisms can dictate immune cell function and fibrosis but also highlight the potential for targeting this axis in therapeutic strategies.

Comparison with Existing Internal Articles

Several internal resources expand on the foundational roles of macrophage biology and metabolic modulation in fibrosis and immune response. For instance, the article “Recombinant Mouse M-CSF: Metabolic Modulation and Macrophage Phenotypes” explores the influence of M-CSF on macrophage metabolism and polarization, directly relevant to the reference study’s focus on metabolic reprogramming in PF. Similarly, “Recombinant Mouse Macrophage Colony Stimulating Factor: Mechanisms & Benchmarks” discusses M-CSF’s role in macrophage activation and inflammatory response modulation. While these articles focus on upstream cytokine signaling and its impact on macrophage behavior, the present study offers a new layer of mechanistic insight by connecting m6A-mediated mRNA stabilization to downstream metabolic and phenotypic outcomes. Together, these perspectives reinforce the centrality of macrophage biology in fibrosis and support the integration of cytokine and epitranscriptomic research approaches.

Limitations and Transferability

Despite its significant contributions, the study has several limitations:

• Model System Constraints: Findings were derived from mouse models and primary cell cultures. While these systems are informative, further validation in human tissues and clinical samples is essential for translational relevance.
• Focus on a Single Pathway: The study primarily interrogated the IGF2BP1–THBS1–TLR4 axis. Given the complexity of PF, additional regulatory layers and cell types may contribute to disease progression.
• Therapeutic Implications: While the pathway presents clear intervention points, the safety and efficacy of targeting this axis remain to be established in preclinical or clinical settings.

Transferability of these findings to other fibrotic or inflammatory contexts should be approached with caution until further studies provide supporting data.

Protocol Parameters

• Bleomycin-induced PF model: Typically, BLM is administered intratracheally at 2–3 mg/kg in mice to induce lung fibrosis for mechanistic studies.
• IGF2BP1 knockdown: Use siRNA or shRNA transfection in vitro or in vivo delivery systems, with confirmation of knockdown efficiency by qPCR and Western blot.
• Macrophage polarization assays: Assess expression of M1 (e.g., iNOS, TNF-α) and M2 (e.g., Arg1, CD163, CCL18) markers by flow cytometry and qPCR.
• Metabolic measurements: Evaluate glycolytic enzyme levels (HK2, LDHA, PKM2), glucose uptake, lactate production, and ATP content using standard commercial kits or metabolic flux analyzers.
• Protein–RNA and protein–protein interaction studies: Employ RNA immunoprecipitation (RIP) for IGF2BP1–THBS1 mRNA binding and co-immunoprecipitation for THBS1–TLR4 interaction validation.
• Recombinant cytokine supplementation: For macrophage differentiation or functional assays, supplement cultures with species-specific M-CSF at 10–50 ng/mL as a starting point, adjusting based on the cell model and experimental aim (product information).

Research Support Resources

To facilitate studies of macrophage activation, polarization, and metabolic reprogramming, reliable cytokine reagents are essential. Researchers can utilize Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (APExBIO, PM2021) for controlled induction of macrophage proliferation and differentiation in vitro. This reagent enables reproducible modeling of macrophage behavior in fibrotic and metabolic research workflows, supporting robust experimental design in alignment with the approaches described above.